文献速递淋巴瘤

循环肿瘤DNA用于伊布替尼联合纳武利尤单抗治疗淋巴瘤的无创监测

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
PubMed 文献 · Blood Adv · 2021-01-01

本研究基于LYM1002 1/2a期试验,对67例接受伊布替尼联合纳武利尤单抗治疗的淋巴瘤患者连续采集血浆,用LyV4.0深度测序检测ctDNA。基线TP53突变(25.4%)与更短无进展生存期相关,2周期后ctDNA下降>2-log的分子反应与更好疗效相关。

要点

  • 基线ctDNA中TP53突变(25.4%)与更短无进展生存期相关
  • 复发弥漫大B细胞淋巴瘤中28.6%达到分子反应,与最佳疗效和PFS改善相关
  • 治疗2周期后10.3%非缓解者出现新突变,PLCG2为最常见获得突变基因

核心结论

  • ctDNA可用于靶向药物治疗淋巴瘤的无创监测,包括基线突变分析、残留肿瘤负荷定量和耐药突变获取。

研究设计与样本

  • 基于LYM1002 1/2a期试验(NCT02329847)的预设纵向系统血浆采集,纳入基线及第3周期第1天有血样的患者,共分析67例患者的172份ctDNA样本。
  • 采用LyV4.0 ctDNA Cancer Personalized Profiling Deep Sequencing Assay进行检测。

主要发现

  • 基线ctDNA变异中仅TP53突变(25.4%患者检出)与更短无进展生存期相关,且携带基线TP53突变的克隆在治疗中未消失。
  • 在至少有一个基线变异的复发弥漫大B细胞淋巴瘤患者中,28.6%在2周期(28天)治疗后达到ctDNA水平下降>2-log的分子反应,与最佳疗效和改善的无进展生存期相关。
  • 治疗期间克隆演化常见,非缓解者中10.3%在2周期后出现新突变,PLCG2是获得新突变最多的基因。
  • 无患者获得与慢性淋巴细胞白血病中伊布替尼耐药相关的C481S BTK突变。

临床怎么用

  • ctDNA可用于靶向治疗淋巴瘤的临床试验场景中的无创监测,基线TP53突变和分子反应可辅助预后评估。

局限性

  • 本研究为临床试验环境下的概念验证,样本量及治疗背景有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To advance the use of circulating tumor DNA (ctDNA) applications, their broad clinical validity must be tested in different treatment settings, including targeted therapies. Using the prespecified longitudinal systematic collection of plasma samples in the phase 1/2a LYM1002 trial (registered on www.clinicaltrials.gov as NCT02329847), we tested the clinical validity of ctDNA for baseline mutation profiling, residual tumor load quantification, and acquisition of resistance mutations in patients with lymphoma treated with ibrutinib+nivolumab. Inclusion criterion for this ancillary biological study was the availability of blood collected at baseline and cycle 3, day 1. Overall, 172 ctDNA samples from 67 patients were analyzed by the LyV4.0 ctDNA Cancer Personalized Profiling Deep Sequencing Assay. Among baseline variants in ctDNA, only TP53 mutations (detected in 25.4% of patients) were associated with shorter progression-free survival; clones harboring baseline TP53 mutations did not disappear during treatment. Molecular response, defined as a >2-log reduction in ctDNA levels after 2 cycles of therapy (28 days), was achieved in 28.6% of patients with relapsed diffuse large B-cell lymphoma who had ≥1 baseline variant and was associated with best response and improved progression-free survival. Clonal evolution occurred frequently during treatment, and 10.3% new mutations were identified after 2 treatment cycles in nonresponders. PLCG2 was the topmost among genes that acquired new mutations. No patients acquired the C481S BTK mutation implicated in resistance to ibrutinib in CLL. Collectively, our results provide the proof of concept that ctDNA is useful for noninvasive monitoring of lymphoma treated with targeted agents in the clinical trial setting.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bruscaggin A, di Bergamo LT, Spina V, et al. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. Blood Adv. 2021. PMID: 34500472. doi:10.1182/bloodadvances.2021004528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。